Adam Townsend - Dec 5, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Commercial Officer
Signature
/s/ David Watson, attorney-in-fact for Adam Townsend
Stock symbol
APLS
Transactions as of
Dec 5, 2022
Transactions value $
-$327,350
Form type
4
Date filed
12/7/2022, 07:30 AM
Previous filing
Nov 7, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise -$75.5K -5K -9.45% $15.09 47.9K Dec 5, 2022 Direct F1
transaction APLS Common Stock Sale -$252K -5K -10.44% $50.38 42.9K Dec 5, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -5K -1.6% $0.00 308K Dec 5, 2022 Common Stock 5K $15.09 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2022.
F2 This stock option was granted on 11/16/2018 and is fully vested.